Open AccessEffect of photobiomodulation treatment in the sublingual, radial artery region, and along the spinal column in individuals with multiple sclerosis
Author(s) -
Tamiris Silva,
Fernanda Cordeiro da Silva,
Andréa Oliver Gomes,
Ariane Viana,
Marcela Letícia Leal Gonçalves,
Maria Isabel Rodrigues,
Anna Carolina Ratto Tempestini Horliana,
Daniela de Fátima Teixeira da Silva,
Maria Cristina Chavantes,
Yára Dadalti Fragoso,
Luciana Prats Branco,
Lara Jansiski Motta,
Kristianne Porta Santos Fernandes,
Raquel Agnelli MesquitaFerrari,
Sandra Kalil Bussadori
Publication year - 2018
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000010627
Subject(s) - medicine , multiple sclerosis , spinal cord injury , experimental autoimmune encephalomyelitis , neuroprotection , inflammation , clinical trial , anesthesia , spinal cord , pathology , pharmacology , immunology , psychiatry
Abstract Background: Multiple sclerosis (MS) is an autoimmune disease, for which the forms of treatment are medication and rehabilitation. However, in vitro and in vivo studies have demonstrated that photobiomodulation can be an effective treatment modality for inflammatory diseases, including MS. Photobiomodulation has a broad range of benefits, such as the avoidance of cell and tissue death, the stimulation of healing and injury repair, reductions in pain, edema and inflammation, cell proliferation, and even apoptosis. The outcomes of photobiomodulation include the regeneration of cells, the stimulation of the growth of Schwann cells, a reduction in spasticity, functional improvements, a reduction in nitric oxide levels, and the upregulation of the cytokine IL10, demonstrating that this therapeutic modality can offer neuroprotection. Methods: A randomized, controlled, double-blind, clinical trial is proposed. The patients will be divided into 6 groups. Groups 1 and 2 will receive sham and active photobiomodulation in the sublingual region, respectively. Groups 3 and 4 will receive sham and active photobiomodulation along the spinal cord, respectively. Group 5 will receive placebo treatment with photobiomodulation on the skin in the region of the radial artery with a specific bracelet. Group 6 will be treated with photobiomodulation on the skin in the region of the radial artery. Discussion: Treatment for MS is directed at the immune response and slowing the progression of the disease. This is one of the first clinical trials involving photobiomodulation in the sublingual region and along the spinal cord, which could help establish a promising new form of nonpharmacological treatment for autoimmune diseases. This is one of the first clinical trials with sublingual photobiomodulation and along the spinal cord that could help establish a new form of promising treatment of the disease associated with pharmacological treatment.